MRM
MRM
MEDIROM Healthcare Technologies Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $611.99M ▲ | $539.23M ▲ | $63.43M ▲ | 10.36% ▲ | $8.02 ▲ | $83.37M ▲ |
| Q2-2025 | $21.85M ▼ | $8.02M ▼ | $-4.65M ▼ | -21.29% ▼ | $-0.59 ▼ | $-3.95M ▼ |
| Q4-2024 | $4.82B ▲ | $1.05B ▼ | $730.94M ▲ | 15.15% ▲ | $68.9 ▲ | $828.07M ▲ |
| Q2-2024 | $3.48B ▼ | $1.21B ▲ | $-582.18M ▼ | -16.75% ▼ | $-118.56 ▼ | $-440.57M ▼ |
| Q4-2023 | $3.59B | $971.23M | $470.47M | 13.12% | $86.32 | $70.43M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $20.14M ▲ | $4.16B ▲ | $2.82B ▲ | $1.33B ▲ |
| Q2-2025 | $268.75K ▼ | $55.36M ▼ | $51.91M ▼ | $3.07M ▼ |
| Q4-2024 | $335.56M ▲ | $8.09B ▲ | $6.9B ▲ | $933.27M ▲ |
| Q2-2024 | $144.65M ▲ | $5.83B ▼ | $6.19B ▼ | $-363.2M ▼ |
| Q4-2023 | $132.85M | $6.85B | $6.63B | $210.88M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-4.65M ▼ | $-2.37M ▲ | $-257.25K ▲ | $629.01K ▼ | $-1.87M ▼ | $-2.48M ▲ |
| Q4-2024 | $720.37M ▲ | $-545.96M ▲ | $-401.84M ▼ | $1.13B ▲ | $184.75M ▲ | $-1.09B ▼ |
| Q2-2024 | $-582.18M ▼ | $-785.72M ▼ | $381.62M ▲ | $60.79M ▼ | $144.65M ▲ | $-804.41M ▼ |
| Q4-2023 | $470.47M ▲ | $-21.7M ▲ | $-252.11M ▼ | $257.27M ▲ | $-8.42M ▲ | $-101.3M ▲ |
| Q2-2023 | $-355.07M | $-610.04M | $175.65M | $-53.34M | $-545.36M | $-666.28M |
What's strong about this company's cash flow?
The company dramatically reduced its cash burn this quarter, mainly by selling down inventory and collecting receivables. Operating losses are much smaller, and no new shares were issued, so dilution is not a concern right now.
What are the cash flow concerns?
MRM is still losing money and burning cash, with only $226,000 left—barely enough to last another quarter. The improvement came from one-time working capital moves, not from turning the business profitable, and the company is highly dependent on borrowing.
5-Year Trend Analysis
A comprehensive look at MEDIROM Healthcare Technologies Inc.'s financial evolution and strategic trajectory over the past five years.
Key positives include strong reported profitability metrics, exceptionally high service-level margins, and a sizable equity and retained-earnings base. The company’s hybrid salon-plus-tech model, the distinctive battery-free wearable, and its corporate and government-facing platforms provide multiple avenues for growth. Strategic partnerships, such as the World ID collaboration, highlight its ability to position itself at the crossroads of wellness, technology, and digital identity.
Major concerns center on cash and leverage. The business is burning substantial cash despite accounting profits, investing heavily while relying on debt and equity issuance to stay liquid. High operating overhead, significant interest costs, and a balance sheet with considerable short-term debt and limited cash increase financial fragility. Competitive and regulatory pressures in health data and digital identity further add to operational risk, and limited multi-year data makes it difficult to gauge the stability of current performance.
The outlook is finely balanced. If MEDIROM can translate its innovation pipeline and partnerships into sustained revenue growth and improved cash generation—while steadily strengthening its balance sheet—the combination of high gross margins and a differentiated business model could support a more resilient franchise. Conversely, if cash burn persists, leverage remains high, or competitive and regulatory headwinds intensify, the current strategy could come under strain. Future results will hinge on disciplined execution, effective capital allocation, and the company’s ability to convert its technological and ecosystem advantages into durable, cash-backed value.
About MEDIROM Healthcare Technologies Inc.
https://medirom.co.jpMEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in two segments, Relaxation Salon and Digital Preventative Healthcare.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $611.99M ▲ | $539.23M ▲ | $63.43M ▲ | 10.36% ▲ | $8.02 ▲ | $83.37M ▲ |
| Q2-2025 | $21.85M ▼ | $8.02M ▼ | $-4.65M ▼ | -21.29% ▼ | $-0.59 ▼ | $-3.95M ▼ |
| Q4-2024 | $4.82B ▲ | $1.05B ▼ | $730.94M ▲ | 15.15% ▲ | $68.9 ▲ | $828.07M ▲ |
| Q2-2024 | $3.48B ▼ | $1.21B ▲ | $-582.18M ▼ | -16.75% ▼ | $-118.56 ▼ | $-440.57M ▼ |
| Q4-2023 | $3.59B | $971.23M | $470.47M | 13.12% | $86.32 | $70.43M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $20.14M ▲ | $4.16B ▲ | $2.82B ▲ | $1.33B ▲ |
| Q2-2025 | $268.75K ▼ | $55.36M ▼ | $51.91M ▼ | $3.07M ▼ |
| Q4-2024 | $335.56M ▲ | $8.09B ▲ | $6.9B ▲ | $933.27M ▲ |
| Q2-2024 | $144.65M ▲ | $5.83B ▼ | $6.19B ▼ | $-363.2M ▼ |
| Q4-2023 | $132.85M | $6.85B | $6.63B | $210.88M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-4.65M ▼ | $-2.37M ▲ | $-257.25K ▲ | $629.01K ▼ | $-1.87M ▼ | $-2.48M ▲ |
| Q4-2024 | $720.37M ▲ | $-545.96M ▲ | $-401.84M ▼ | $1.13B ▲ | $184.75M ▲ | $-1.09B ▼ |
| Q2-2024 | $-582.18M ▼ | $-785.72M ▼ | $381.62M ▲ | $60.79M ▼ | $144.65M ▲ | $-804.41M ▼ |
| Q4-2023 | $470.47M ▲ | $-21.7M ▲ | $-252.11M ▼ | $257.27M ▲ | $-8.42M ▲ | $-101.3M ▲ |
| Q2-2023 | $-355.07M | $-610.04M | $175.65M | $-53.34M | $-545.36M | $-666.28M |
What's strong about this company's cash flow?
The company dramatically reduced its cash burn this quarter, mainly by selling down inventory and collecting receivables. Operating losses are much smaller, and no new shares were issued, so dilution is not a concern right now.
What are the cash flow concerns?
MRM is still losing money and burning cash, with only $226,000 left—barely enough to last another quarter. The improvement came from one-time working capital moves, not from turning the business profitable, and the company is highly dependent on borrowing.
5-Year Trend Analysis
A comprehensive look at MEDIROM Healthcare Technologies Inc.'s financial evolution and strategic trajectory over the past five years.
Key positives include strong reported profitability metrics, exceptionally high service-level margins, and a sizable equity and retained-earnings base. The company’s hybrid salon-plus-tech model, the distinctive battery-free wearable, and its corporate and government-facing platforms provide multiple avenues for growth. Strategic partnerships, such as the World ID collaboration, highlight its ability to position itself at the crossroads of wellness, technology, and digital identity.
Major concerns center on cash and leverage. The business is burning substantial cash despite accounting profits, investing heavily while relying on debt and equity issuance to stay liquid. High operating overhead, significant interest costs, and a balance sheet with considerable short-term debt and limited cash increase financial fragility. Competitive and regulatory pressures in health data and digital identity further add to operational risk, and limited multi-year data makes it difficult to gauge the stability of current performance.
The outlook is finely balanced. If MEDIROM can translate its innovation pipeline and partnerships into sustained revenue growth and improved cash generation—while steadily strengthening its balance sheet—the combination of high gross margins and a differentiated business model could support a more resilient franchise. Conversely, if cash burn persists, leverage remains high, or competitive and regulatory headwinds intensify, the current strategy could come under strain. Future results will hinge on disciplined execution, effective capital allocation, and the company’s ability to convert its technological and ecosystem advantages into durable, cash-backed value.

CEO
Kouji Eguchi
Compensation Summary
(Year )
Ratings Snapshot
Rating : C+
Price Target
Institutional Ownership
JANE STREET GROUP, LLC
Shares:155.07K
Value:$176.78K
UBS GROUP AG
Shares:26.55K
Value:$30.26K
TWO SIGMA SECURITIES, LLC
Shares:13.98K
Value:$15.93K
Summary
Showing Top 3 of 8

